The development of new positron-emission tomography (PET) tracers is enabling researchers and clinicians to image an increasingly wide array of biological targets and processes. However, the increasing number of different tracers creates challenges for their production at radiopharmacies. While historically it has been practical to dedicate a custom-configured radiosynthesizer and hot cell for the repeated production of each individual tracer, it is becoming necessary to change this workflow. Recent commercial radiosynthesizers based on disposable cassettes/kits for each tracer simplify the production of multiple tracers with one set of equipment by eliminating the need for custom tracer-specific modifications. Furthermore, some of these radiosynthesizers enable the operator to develop and optimize their own synthesis protocols in addition to purchasing commercially-available kits. In this protocol, we describe the general procedure for how the manual synthesis of a new PET tracer can be automated on one of these radiosynthesizers and validated for the production of clinical-grade tracers. As an example, we use the ELIXYS radiosynthesizer, a flexible cassette-based radiochemistry tool that can support both PET tracer development efforts, as well as routine clinical probe manufacturing on the same system, to produce [ , a PET tracer to measure in vivo deoxycytidine kinase (dCK) enzyme activity. Translating a manual synthesis involves breaking down the synthetic protocol into basic radiochemistry processes that are then translated into intuitive chemistry "unit operations" supported by the synthesizer software. These operations can then rapidly be converted into an automated synthesis program by assembling them using the drag-and-drop interface. After basic testing, the synthesis and purification procedure may require optimization to achieve the desired yield and purity. Once the desired performance is achieved, a validation of the synthesis is carried out to determine its suitability for the production of the radiotracer for clinical use.
Introduction
An increasing array of biological targets can be dynamically visualized in living subjects via the molecular imaging modality PET. PET provides in vivo assays of specific biological, biochemical, and pharmacological processes by using specific radiotracers (molecules labeled with positronemitting radionuclides) that are injected into the subject prior to imaging 1 . The increased use of PET to study a wide variety of these processes in basic science and clinical research 2, 3, 4 , and in the discovery, development, and clinical use of drugs in patient care 5, 6 , is leading to a growing demand for diverse radiotracers 7, 8 . To avoid radiation exposure to the radiochemist and to ensure a reproducible production of these shortlived tracers, they are typically manufactured using an automated radiosynthesizer operating inside a "hot cell". Recent radiosynthesizers use a disposable-cassette/kit architecture to simplify the task of complying with clinical-grade manufacturing while also providing the flexibility to prepare multiple types of radiotracers simply by swapping out cassettes 9 . However, in early clinical stages, there are usually no commerciallyavailable cassettes/kits to perform the automated radiosynthesis; consequently, PET drug manufacturing facilities struggle to customize systems to implement cGMP-grade tracer production capabilities within a suitable timeframe and at a reasonable cost. Thus, radiosynthesizers have been developed that combine the cassette/kit architecture with features to facilitate the development and optimization of tracers.
The ELIXYS FLEX/CHEM (ELIXYS) is an example of a flexible cassette-based radiosynthesizer with a wide reagent, solvent, and reaction temperature compatibility 10 . It has three reaction vessels and uses a robotic mechanism to dynamically configure the fluid pathway as required by any particular synthesis protocol 11 , by simply changing reagents and not the configuration of the system. Others 16 , this protocol builds further on these efforts and describes additional modifications needed for the clinical production of this tracer, including the integration of fully-automated purification and formulation, protocol validation, and quality-control testing. Figure 1 , the identification of highlevel steps is shown in Figure 2A , and the breakdown into processes is shown in Figure 2B . 2. Using paper and pen, map each process into the individual unit operations provided by the synthesizer software. As an example, an analysis of the mapping of basic processes in the synthesis of [ 18 F]CFA to suitable unit operations in the synthesizer software 13 is shown in Figure 2C .
3. Using the radiosynthesizer programming interface, create a blank program and append each of the identified unit operations in sequence by clicking the Menu button (top left) and selecting Sequences, and then clicking the New Sequence button. For each unit operation identified in step 1.2.2.2, drag the unit operation from the available operations to the filmstrip view and click or type to fill out the desired value of each parameter of the unit operation. Figure 3 shows an example of the interface when all the operations to synthesize [ 3. Develop quality control (QC) testing procedures 1. Using a non-radioactive reference of the final product and samples of potential chemical impurities, develop an analytical radio-HPLC and/or radio-thin layer chromatography (radio-TLC) method with sufficient separation of species for the determination of chemical purity, molar activity, radiochemical purity, and radiochemical identity. Validate the analytical method(s) for repeatability and linearity and determine the detection and quantification limits. 2. Similarly, develop and validate a gas chromatography method to analyze volatile impurities (e.g., residual amounts of solvents that are used during the synthesis). 3. Develop and validate analytical assays that allow the detection and quantification of other potential impurities (e.g., cryptand 222 via the standard color spot test). 4. Use standard procedures for the determination of sterility, pH, radionuclidic identity, radionuclidic purity, radioactivity concentration, product volume, and endotoxin levels.
4. Perform synthesis validation 1. Establish standard operating procedures (SOPs) for the synthesis and QC testing procedures and integrate a materials and equipment tracking system compliant with current good manufacturing practice (cGMP) requirements. 2. Validate the synthesis procedures via three independent and consecutive production runs at the same radioactivity levels as intended for clinical manufacturing following the SOPs. Document the synthesis performance and results of QC testing. 3. All consecutive validation runs must pass the pre-set QC limits. If a validation run fails, repeat the whole validation process after appropriately addressing the root cause of the failure. Ensure the waste container is empty. Place waste lines from the purification/formulation subsystem to the waste container (i.e., sample loop 1 waste line, HPLC subsystem waste line, and the syringe pump waste line). 10. Connect the HPLC input lines. Place HPLC mobile phase input line "A" in a container of 25 mM ammonium acetate and HPLC mobile phase input line "B" in a container of EtOH. 11. Equilibrate the purification/formulation subsystem and HPLC column.
Example: Automated Synthesis of [
1. Open the control page for the purification/formulation module in the software by selecting HPLC from the main menu (top left). By default, the Purification tab will already be selected. (This page is shown in Figure 6 .) 2. Set the flow rate to 5.0 mL/min at the defined solvent composition and choose which column position the purification column is installed in. Turn on the HPLC pump in the isocratic mode for at least 10 min. 3. Rinse the product line and all fraction collection lines with the mobile phase, each for 1 min. 4. Rinse each HPLC sample loop and HPLC sample loop transfer tubing with 10 mL of the mobile phase using a syringe.
12. Connect the purification/formulation subsystem syringe pump input lines. Use concentrated sodium chloride (90 mg/mL) for the Elute line and 0.9% saline for the Reconstitute line. 13. Prime the formulation subsystem.
1. Navigate to the Formulation tab of the purification/formulation control page. 2. To prime the concentrated sodium chloride (90 mg/mL), select the Elute tab. Press Initialize to initialize the syringe pump. Dispense 5 mL. 3. To prime the 0.9% saline, select the Reconstitute tab. Dispense 5 mL.
Representative Results
A method to automate the production of [ While designing the synthesis, the choice of reagents and their quality assurance is of particular importance for clinical use. Ensuring the correct programming and proper connections by performing a mock synthesis (solvents only) is imperative to eliminate unexpected errors when the synthesis is performed with radioactivity. The subsequent synthesis optimizations (solvents, volumes, amounts, temperatures, reaction times, and purification conditions) depend on the specific PET tracer in development. During these experiments, particular focus should be shone on the chemical and radiochemical purity of the final product that can be achieved, as these must meet stringent requirements for clinical use. A synthesis that reliably produces a pure product in lower but sufficient activity yields is usually preferred over a higher-yielding process that has a risk to fail sporadically. Once the synthesis has been adequately optimized, the final process needs to undergo validation tests (a regulatory requirement) to ensure clinical suitability. The validated synthesis method can then be used to produce the PET tracer for clinical use. When synthesizing a PET tracer according to a validated method, the standard operating procedures should be thoroughly followed. To ensure compliance, the software is programmed to have the operator confirm the completion of key steps via a pre-run checklist after clicking on Run to start the synthesis. While the system will perform the synthesis in an automated fashion, the purification step requires manual intervention. The operator must, therefore, closely observe the chromatographic screen during the HPLC purification step, and manually input in real-time when to start and stop collecting the product fraction.
Within our automation and optimization efforts for the [ 18 F]CFA synthesis, we have streamlined the semi-preparative HPLC purification method of the product mixture by using an injectable solvent system consisting of ammonium acetate solution and EtOH; our previous method required an additional step to exchange the solvent after purification 16 . The subsequent formulation process, thus, needs only to reduce the EtOH content of the collected fraction to permitted levels, and to ensure its isotonicity, both of which can be accomplished by dilution. The formulation step was performed using a second program consisting of a single Formulation unit operation to allow variable volume additions of NaCl-solutions to the purified product fraction via the formulation module to account for the variable volume obtained after HPLC purification. If the collected product fraction volume was set to be constant instead, the Formulation unit operation could be included in the main synthesis program, avoiding the need for an independent program. An alternative approach to avoid manual intervention would be to use the full functionality of the formulation module (e.g., dilute the purified tracer with water, trap on a C18 solid-phase extraction cartridge, wash it, elute it with a fixed volume of EtOH, and finally, dilute it with a fixed volume of saline).
The technique presented here for automating and validating a synthesis protocol for clinical use is intended to be quite general. Through the choice of radiosynthesizer (ELIXYS), a wide range of syntheses can be automated and validated. This includes complex 3-pot syntheses, or syntheses involving high temperatures of volatile solvents. Optimizing a synthesis can be achieved by changing the parameters of the software program. The synthesizer has features to monitor the impact of changes, such as positioning the reaction vessels for the removal of samples for radio-TLC or radio-HPLC analysis. However, without system modifications, the system currently does not allow for the handling of very low reagent volumes (~5 -20 µL), intermediate product distillation, or the handling of [ Ga, or other radiometals. If the manual synthesis to be automated contains such steps and they cannot be circumvented, automation and validation with another radiosynthesizer platform may be appropriate.
Although this work has focused on the development of a protocol for the automated production of [ User-established protocols can be uploaded to and downloaded from the SOFIE Probe Network, a web portal for sharing synthesis programs and associated documentation among different radiopharmacy sites 27 . This can avoid a duplication of efforts in the community and facilitate multi-center clinical studies involving PET imaging.
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